Trium Capital LLP Invests $858,000 in Zoetis Inc. $ZTS

Trium Capital LLP bought a new position in Zoetis Inc. (NYSE:ZTS) during the third quarter, according to its most recent filing with the SEC. The firm bought 5,863 shares of the company’s stock, valued at approximately $858,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Nova Wealth Management Inc. bought a new position in shares of Zoetis in the first quarter valued at $25,000. 1248 Management LLC acquired a new stake in shares of Zoetis in the 1st quarter worth about $27,000. Saudi Central Bank acquired a new stake in shares of Zoetis in the 1st quarter worth about $29,000. REAP Financial Group LLC lifted its position in Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 131 shares in the last quarter. Finally, NewSquare Capital LLC boosted its stake in Zoetis by 69.1% during the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 1.6%

Shares of NYSE:ZTS opened at $125.50 on Friday. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $177.40. The company has a market capitalization of $55.31 billion, a PE ratio of 21.13, a price-to-earnings-growth ratio of 2.73 and a beta of 0.97. The business has a fifty day moving average price of $127.41 and a two-hundred day moving average price of $143.41. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The firm’s quarterly revenue was up .5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be paid a $0.53 dividend. The ex-dividend date is Tuesday, January 20th. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. Zoetis’s dividend payout ratio is presently 33.67%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ZTS. Stifel Nicolaus lowered their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday, November 18th. HSBC set a $140.00 price target on Zoetis in a research report on Wednesday, December 10th. UBS Group cut their price objective on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a report on Wednesday, November 5th. Bank of America downgraded shares of Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 target price for the company. in a report on Monday, December 15th. Finally, BTIG Research reissued a “buy” rating and set a $160.00 price target on shares of Zoetis in a research report on Wednesday, December 3rd. Six investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $160.18.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.